Patents by Inventor Richard F. Selden

Richard F. Selden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6048724
    Abstract: The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) that encodes erythropoietin or an insulinotropin (e.g., derivatives of glucagon-like peptide 1 (GLP-1)), methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains that express erythropoietin or an insulinotropin, methods of gene therapy in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: April 11, 2000
    Assignee: Transkaryotic Therapies Inc.
    Inventors: Richard F Selden, Douglas Treco, Michael W. Heartlein
  • Patent number: 6048729
    Abstract: The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes a desired (e.g., a therapeutic) product or is itself a desired (e.g., therapeutic) product, methods by which primary and secondary cells are transfected to include exogenous genetic material, methods of producing clonal cell strains or heterogenous cell strains, methods of gene therapy in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells.
    Type: Grant
    Filed: November 4, 1994
    Date of Patent: April 11, 2000
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Richard F Selden, Douglas Treco, Michael W. Heartlein
  • Patent number: 5994127
    Abstract: The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes erythropoietin or an insulinotropin [e.g., derivatives of glucagon-like peptide 1(GLP-1)], methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains which express eruthropoietin or an insulinotropin, methods of gene therapy in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells.
    Type: Grant
    Filed: November 4, 1994
    Date of Patent: November 30, 1999
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Richard F Selden, Douglas Treco, Michael W. Heartlein
  • Patent number: 5968502
    Abstract: The present invention relates to transfected primary, secondary, and immortalized cells of vertebrate origin particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes a desired (e.g., a therapeutic) product or is itself a desired (e.g., therapeutic) product, methods by which primary, secondary and immortalized cells are transfected to include exogenous genetic material, including DNA targeting by homologous recombination, methods for the activation and amplification of endogenous cellular genes, methods by which cells useful for large-scale protein production can be obtained, methods of producing clonal cell strains or heterogenous cell strains, and methods of gene therapy in which transfected primary, secondary or immortalized cells are used.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: October 19, 1999
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Douglas Treco, Michael W. Heartlein, Richard F Selden
  • Patent number: 5733761
    Abstract: The present invention relates to transfected primary, secondary and immortalized cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes a desired (e.g., a therapeutic) product or is itself a desired (e.g., therapeutic) product, methods by which primary, secondary and immortalized cells are transfected to include exogenous genetic material, including DNA targeting by homologous recombination, methods for the activation and amplification of endogenous cellular genes, methods by which cells useful for large-scale protein production can be obtained, methods of producing clonal cell strains or heterogenous cell strains, and methods of gene therapy in which transfected primary, secondary or immortalized cells are used.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: March 31, 1998
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Douglas Treco, Michael W. Heartlein, Richard F. Selden
  • Patent number: 5733746
    Abstract: The invention relates to novel human DNA sequences, targeting constructs, and methods for producing novel genes encoding thrombopoietin, DNase I, and .beta.-interferon by homologous recombination. The targeting constructs comprise at least: a) a targeting sequence; b) a regulatory sequence; c) an exon; and d) a splice-donor site. The targeting constructs, which can undergo homologous recombination with endogenous cellular sequences to generate a novel gene, are introduced into cells to produce homologously recombinant cells. The homologously recombinant cells are then maintained under conditions which will permit transcription of the novel gene and translation of the mRNA produced, resulting in production of either thrombopoietin, DNase I, or .beta.-interferon. The invention further relates to a methods of producing pharmaceutically useful preparations containing thrombopoietin, DNase I, or .beta.
    Type: Grant
    Filed: March 17, 1995
    Date of Patent: March 31, 1998
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Douglas A. Treco, Michael W. Heartlein, Brian M. Hauge, Richard F. Selden
  • Patent number: 5641670
    Abstract: The invention relates to constructs comprising: a) a targeting sequence; b) a regulatory sequence; c) an exon; and d) an unpaired splice-donor site. The invention further relates to a method of producing protein in vitro or in vivo comprising the homologous recombination of a construct as described above within a cell. The homologously recombinant cell is then maintained under conditions which will permit transcription and translation, resulting in protein expression. The present invention further relates to homologously recombinant cells, including primary, secondary, or immortalized vertebrate cells, methods of making the cells, methods of homologous recombination to produce fusion genes, methods of altering gene expression in the cells, and methods of making a protein in a cell employing the constructs of the invention.
    Type: Grant
    Filed: May 13, 1994
    Date of Patent: June 24, 1997
    Assignee: Transkaryotic Therapies, Inc.
    Inventors: Douglas A. Treco, Michael W. Heartlein, Richard F. Selden